Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $295,679 | $252,329 | $258,615 | $451,799 |
| - Cash | $56,746 | $32,786 | $24,459 | $18,890 |
| + Debt | $59,965 | $60,579 | $41,553 | $30,565 |
| Enterprise Value | $298,898 | $280,122 | $275,709 | $463,474 |
| Revenue | $179,278 | $116,882 | $120,242 | $149,236 |
| % Growth | 53.4% | -2.8% | -19.4% | – |
| Gross Profit | $160,631 | $109,772 | $118,493 | $148,153 |
| % Margin | 89.6% | 93.9% | 98.5% | 99.3% |
| EBITDA | $28,512 | -$16,981 | -$53,868 | -$11,287 |
| % Margin | 15.9% | -14.5% | -44.8% | -7.6% |
| Net Income | $17,485 | -$25,091 | -$58,573 | -$17,914 |
| % Margin | 9.8% | -21.5% | -48.7% | -12% |
| EPS Diluted | 0.99 | -1.44 | -3.4 | -1.1 |
| % Growth | 168.7% | 57.6% | -209.1% | – |
| Operating Cash Flow | $31,471 | -$5,743 | -$73,758 | $5,878 |
| Capital Expenditures | -$396 | -$15,000 | -$450 | -$627 |
| Free Cash Flow | $31,075 | -$20,743 | -$74,208 | $5,251 |